PEDIATRICS Vol. 76 No. 2 August 1985, pp. 322-324
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Hemophilus Type b Polysaccharide Vaccine

Committee on Infectious Diseases

Hemophilus influenzae type b is a major cause of serious, invasive infections in infants and children. It causes most cases of bacterial meningitis, nearly all cases of epiglottitis, and a substantial number of the cases of bacterial pneumonia, septic arthritis, febrile bacteremia, and facial cellulitis in young children. H influenzae strains causing otitis media and sinusitis are usually nonencapsulated.

In spite of advances in the diagnosis and therapy of H influenzae type b infections, the mortality and morbidity remain appreciable. Approximately 3% to 10% of children with H influenzae type meningitis die, and 25% to 50% of survivors are reported to have neurologic sequelae. Epiglottitis is a lifethreatening emergency and may result in sudden, unpredictable airway obstruction.

The incidence of H influenzae type b infection is highest during infancy, with the peak between 6 and 12 months of age1 (Table); epiglottitis is an exception; the mean age of occurrence is 44 months.1 Other risk factors include the following: (1) household contact with a patient with invasive H influenzae type b disease2; (2) day care attendance3; (3) functional or anatomic asplenia including sickle cell anemia4; (4) immunosuppression, including patients with Hodgkin disease5; and (5) agammaglobulinemia.6 An increased incidence of invasive H influenzae type b disease has also been reported in certain population groups, such as American Indians,7,8 Alaskan Eskimos,9 and blacks.10 Genetic factors have also been implicated in disease susceptibility.11

CLINICAL STUDIES

A vaccine consisting of the purified H influenzae type b capsular polysaccharide has been licensed for use in the United States.




This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
H. Peltola
Worldwide Haemophilus influenzae Type b Disease at the Beginning of the 21st Century: Global Analysis of the Disease Burden 25 Years after the Use of the Polysaccharide Vaccine and a Decade after the Advent of Conjugates
Clin. Microbiol. Rev., April 1, 2000; 13(2): 302 - 317.
[Abstract] [Full Text] [PDF]

Home page
 The Journal of the Royal Society for the Promotion of HealthHome page
A. K.C. Leung and T. Jadavji
Polysaccharide vaccine for prevention of Haemophilus influenzae type b disease
The Journal of the Royal Society for the Promotion of Health, October 1, 1988; 108(5): 180 - 181.


Home page
 CLIN PEDIATRHome page
J. R. Gilsdorf
Use of the Haemophilus influenzae Type b Vaccine Among Preschool Attendees
Clinical Pediatrics, June 1, 1988; 27(6): 285 - 288.
[Abstract] [PDF]

Home page
 CLIN PEDIATRHome page
S. R. Nesheim and W. D. Wilcox
Systemic Hemophilus Influenzae Disease in Children: A 10-Year Retrospective Study of an Urban Hospital Population
Clinical Pediatrics, December 1, 1986; 25(12): 605 - 609.
[Abstract] [PDF]